Company
GT Medical Technologies
GammaTile is the first and only tile-based radiation therapy for the treatment of operable brain tumors
Also known as GT Medical Technologies, Inc, GTMedical Technologies
- Business model
- B2B
- Customers
- patients with newly diagnosed malignant (cancerous) and recurrent brain tumors
- Legal name
- GT Medical Technologies, Inc
Claim, correct or request removal
Record updated 19 October 2026
About
GammaTile® is an innovative approach to brain tumor treatment. By delivering precisely targeted radiation therapy – directly inside the tumor site where and when it is most needed – GammaTile helps reduce the risk of tumor regrowth, while protecting healthy brain tissue.
Funding snapshot
- Total raised
- $115MSEC form D sum, as of 2026-09-29Source (opens in a new tab)
- Latest round
- Undisclosed, $50.1M2026-05-08
Funding rounds
- Round, 2026
- $50.1M2026-05-08, SEC form D sold
- Round, 2024
- $53.3M2024-12-23, SEC form D sold, 37 investors
- Round, 2024
- $218K2024-04-12, SEC form D sold, 1 investor
- Round, 2023
- $37.4M2023-03-20, SEC form D sold, 33 investors
- Round, 2020
- $15.5M2020-11-13, SEC form D sold, 15 investors
- Round, 2018
- $5.6M2018-11-14, SEC form D sold, 30 investors
- Round, 2017
- $1.9M2017-12-29, SEC form D sold, 4 investors
- Round, 2017
- $510K2017-12-06, SEC form D sold, 5 investors
Products
- Web
- GammaTile
Loading relationship preview